iASPP and METTL3 are independent prognostic factors for poor survival in early stage squamous cell cervical cancer patients, suggesting that iASPP and METTL3 might serve as novel potential prognostic markers and therapeutic targets for treatment of cervical cancer. This evidence concerns the gene METTL3 and cervical squamous cell carcinoma.